Evidence Grading Methodology
▼Our grading methodology is inspired by Examine.com's evidence-based approach, adapted specifically for the peptide research landscape. Each compound-outcome pair is independently evaluated.
Evidence Grade
A
Grade A — Multiple randomized controlled trials (RCTs) in humans with consistent findings. Strong, reproducible evidence.
B
Grade B — Limited RCTs, strong observational studies, or robust animal data with mechanistic plausibility. Promising but not definitive.
C
Grade C — Preliminary research, case reports, in vitro studies, or limited and conflicting evidence. Requires further investigation.
D
Grade D — Insufficient evidence, theoretical basis only, or single low-quality study. Not supported for clinical conclusions.
Direction of Effect
- ↑↑ Strong Increase — Consistent, clinically significant increase observed
- ↑ Minor Increase — Trend toward increase or modest effect size
- ↔ No Change — No significant effect observed (can be a positive finding)
- ↓ Minor Decrease — Trend toward decrease or modest effect size
- ↓↓ Strong Decrease — Consistent, clinically significant decrease observed
Magnitude
- High — Large effect size; clinically meaningful change relative to placebo/control
- Moderate — Moderate effect size; potentially clinically relevant
- Low — Small effect size; statistically significant but marginal clinical relevance
- Negligible — Minimal or no meaningful effect beyond placebo
Confidence Score
The confidence percentage in Outcome View reflects our overall confidence in the direction and magnitude of effect, considering study quality, sample sizes, consistency of findings, and mechanistic plausibility. It is not a statistical confidence interval.
Limitations
Many peptides lack robust human clinical data. Animal and in vitro research, while informative, may not translate directly to human outcomes. Off-label and research-use peptides may have limited or no regulatory approval. This matrix is a research reference tool, not clinical guidance.
